WO2003063780A3 - Therapeutic composition for treatment of cancer by arginine depletion - Google Patents

Therapeutic composition for treatment of cancer by arginine depletion Download PDF

Info

Publication number
WO2003063780A3
WO2003063780A3 PCT/US2003/002342 US0302342W WO03063780A3 WO 2003063780 A3 WO2003063780 A3 WO 2003063780A3 US 0302342 W US0302342 W US 0302342W WO 03063780 A3 WO03063780 A3 WO 03063780A3
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
treatment
composition
cancer
allowing
Prior art date
Application number
PCT/US2003/002342
Other languages
French (fr)
Other versions
WO2003063780A2 (en
Inventor
Slobodan Tepic
Original Assignee
Cancer Treat S Internat
Orzechowski Karen Lee
Slobodan Tepic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Treat S Internat, Orzechowski Karen Lee, Slobodan Tepic filed Critical Cancer Treat S Internat
Priority to AU2003216109A priority Critical patent/AU2003216109A1/en
Priority to EP03735013A priority patent/EP1499342A2/en
Publication of WO2003063780A2 publication Critical patent/WO2003063780A2/en
Publication of WO2003063780A3 publication Critical patent/WO2003063780A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A therapeutic composition and a method for the treatment of cancer by depletion of arginine without systemic complications comprising an arginine decomposing enzyme and protein breakdown inhibitors, a nitric oxide donor, a pressor peptide, and prostacyclin. The composition may further include an amino acid mixture lacking arginine, an antidote for cyanide, blood plasma or its derivatives, and/or a preparation of arginine. The arginine decomposing enzyme may modified to increase circulation half-life and can be type I liver arginase, or type II of human or animal, partially purified, or recombinant, or even bacterial origin. It may be administered as a drug or released from the patient's own tissue. Endogenous production of arginine, particularly via so-called intestinal-kidney axis, can be beneficially inhibited at several enzymatic steps, allowing for deeper reductions of circulating arginine. Different components of the composition may be administered separately, or in suitable mixtures, allowing for needed adjustments during the treatment.
PCT/US2003/002342 2002-01-25 2003-01-27 Therapeutic composition for treatment of cancer by arginine depletion WO2003063780A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003216109A AU2003216109A1 (en) 2002-01-25 2003-01-27 Therapeutic composition for treatment of cancer by arginine depletion
EP03735013A EP1499342A2 (en) 2002-01-25 2003-01-27 Therapeutic composition for treatment of cancer by arginine depletion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35097102P 2002-01-25 2002-01-25
US60/350,971 2002-01-25

Publications (2)

Publication Number Publication Date
WO2003063780A2 WO2003063780A2 (en) 2003-08-07
WO2003063780A3 true WO2003063780A3 (en) 2004-11-11

Family

ID=27662986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002342 WO2003063780A2 (en) 2002-01-25 2003-01-27 Therapeutic composition for treatment of cancer by arginine depletion

Country Status (3)

Country Link
EP (1) EP1499342A2 (en)
AU (1) AU2003216109A1 (en)
WO (1) WO2003063780A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000349A1 (en) * 2002-06-20 2003-12-31 Bio-Cancer Treatment International Limited Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
WO2006058486A1 (en) * 2004-12-03 2006-06-08 Bio-Cancer Treatment International Limited Use of arginase in combination with 5fu and other compounds for treatment of human malignancies
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
US20090068166A1 (en) * 2006-03-17 2009-03-12 Ning Man Cheng Method and composition for protection against radiation
WO2010023195A2 (en) * 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions and methods for treating cancer
US8440184B2 (en) 2008-10-31 2013-05-14 Gma Technologies Llc Compositions of engineered human arginases and methods for treating cancer
AU2010242422B2 (en) * 2009-03-26 2014-12-04 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
US9382525B2 (en) * 2009-03-26 2016-07-05 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
JP2012531893A (en) * 2009-06-29 2012-12-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Arginase formulation and method
CN105112391B (en) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 A kind of people source arginase mutant and its preparation method and application
EP3496743B1 (en) 2016-08-08 2022-02-09 AERase, Inc. Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
TW201910513A (en) * 2017-08-16 2019-03-16 香港商鎧耀波麗堂（香港）有限公司 Amino acid depletion treatment composition and method
MX2020005933A (en) 2017-12-05 2021-01-15 Aerase Inc Method and composition for treating arginase 1 deficiency.
EP4169526A1 (en) * 2021-10-21 2023-04-26 Kyon Biotech AG Arginase based cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261557B1 (en) * 1996-08-16 2001-07-17 Slobodan Tepic Arginine decomposing enzyme therapeutic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261557B1 (en) * 1996-08-16 2001-07-17 Slobodan Tepic Arginine decomposing enzyme therapeutic composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATTHEWS N.E. ET AL: "Nitric Oxide-Mediated Regulation of Chemosensitivity in Cancer Cells", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 93, no. 24, December 2001 (2001-12-01), pages 1879 - 1885, XP002981238 *
RAO C.V. ET AL: "Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor", CARCINOGENESIS, vol. 20, no. 4, April 1999 (1999-04-01), pages 641 - 644, XP002981237 *
RAO C.V. ET AL: "Chemopreventive Properties of a Selective Inducible Nitric Oxide Synthase Inhibitor in Colon Carcinogenesis, Administered Alone or in Combination with Celecoxib, a Selective Cyclooxygenase-2 Inhibitor", CANCER RESEARCH, vol. 62, no. 1, January 2002 (2002-01-01), pages 165 - 170, XP002981236 *

Also Published As

Publication number Publication date
WO2003063780A2 (en) 2003-08-07
EP1499342A2 (en) 2005-01-26
AU2003216109A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2003063780A3 (en) Therapeutic composition for treatment of cancer by arginine depletion
EP2432454B1 (en) Compositions for continuous administration of dopa decarboxylase inhibitors
WO2001054680A3 (en) Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
Mauldin et al. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation
MXPA05006940A (en) Therapeutic formulations for the treatment of beta-amyloid related diseases.
EP2305276A3 (en) Processed lipoaspirate cells for use in therapy
HK1109876A1 (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
WO2004069190A3 (en) Combination therapy for treating protein deficiency disorders
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
BRPI0414455A (en) Methods for Using Regenerative Cells to Treat Peripheral Vascular Disease and Related Disorders
TW200605909A (en) Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
IL172844A0 (en) Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment
IL161177A0 (en) Pharmaceutical preparation useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
CN105579052A (en) Pharmaceutical composition
WO2004108088A3 (en) Methods and compositions for interferon therapy
WO1995018608A1 (en) Method of treating disorders of the animal or human body by administering amino acids
WO2010023195A3 (en) Compositions and methods for treating cancer
WO2004058268A3 (en) Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders
WO2003061728B1 (en) Oral administration of interferon-tau
AU2001236529A1 (en) Combination therapy for cancer
AU2001223953A1 (en) Use of l-carnitine as stabilizing agent of proteins
JP2009284798A (en) Method for producing dipeptidyl peptidase iv inhibitor
EA200800729A1 (en) TREATMENT OF NEVERITIS NOSE NERVE
WO2004098532A3 (en) Methods of reducing an immune response
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003735013

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003735013

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003735013

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP